BioAge Labs (BIOA)
Nasdaq Market Closed
BioAge Labs, Inc. is a clinical-stage biotechnology company developing medicines for metabolic disease by applying insights from the biology of aging. Rather than approaching aging as a single condition, the company studies molecular and physiological changes associated with human aging and uses those findings to identify drug targets that may influence disease processes linked to metabolism, tissue function and resilience.
The company’s platform is built around human datasets intended to connect biological markers of aging with health outcomes. This data-driven approach is designed to help BioAge select targets with evidence from human biology before advancing therapeutic candidates into clinical development. Its strategy reflects a broader trend in biotechnology: using large-scale biological information to improve the probability that experimental drugs address mechanisms that matter in patients.
BioAge is not a diversified commercial drugmaker; it operates as a development-stage company focused on research, clinical trials and pipeline advancement. Its business is organized around the objective of extending healthy human life by targeting molecular contributors to age-related decline. In practical terms, that means its value depends heavily on the progress of its product candidates, the strength of its clinical data, regulatory outcomes and its ability to secure funding or partnerships as programs mature.
For investors and market observers, BioAge represents exposure to the intersection of longevity science and conventional drug development. Its distinguishing feature is the use of aging biology as a framework for treating metabolic disorders, an area with large potential markets but high scientific, clinical and regulatory risk.
Last updated
- Market Cap
- 713.02M
- P/E
- —
- P/FCF
- —
- P/S
- 69.12
- Enterprise Value
- 472.4M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 5885 HOLLIS STREET, EMERYVILLE, CA, 94608
BioAge Labs to Present at Upcoming Investor Conferences
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
Top 3 Biotech Stocks Capitalizing on the AI Revolution
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
BIOA LEGAL NEWS: A Class Action was filed on behalf of BioAge Labs Investors - Contact BFA Law if You Suffered Losses
Deadline Alert: BioAge Labs, Inc. (BIOA) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
BIOA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
BIOA DEADLINE ALERT: BioAge Labs (BIOA) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action
BIOA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
BIOA Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against BioAge Labs, Inc. (BIOA)
BIOA REMINDER: BioAge Labs was Sued for Securities Violations; Investors are Alerted to Contact BFA Law before March 10 Deadline (NASDAQ:BIOA)
BIOA 的重要截止日期：全球頂尖法律顧問 ROSEN 鼓勵損失逾 10 萬美元的 BioAge Labs, Inc. 投資者在對 BIOA 提出證券集體訴訟的重要截止日期 3 月 10 日前聘請律師
BIOA IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – BIOA
BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO– Hagens Berman
BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit – Hagens Berman
BIOA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Kessler Topaz Meltzer & Check, LLP Reminds BIOA Shareholders of Deadline in Securities Fraud Class Action Lawsuit Filed Against BioAge Labs, Inc. (BIOA)
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 713.02M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 472.4M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.88
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 69.12
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -4.66
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 45.79
- EPS
- -2.02
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -88.63M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -23.72%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -22.62%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 24.76
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 24.76
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 15.28
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 399.2K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 16.04
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 2.77M | 3.08M | 2.05M | 2.41M | 1.45M |
| Gross profit | 2.77M | 3.08M | 2.05M | 2.41M | 1.45M |
| Operating income | -25.38M | -28.42M | -23.14M | -24.77M | -16.45M |
| EBITDA | -25.31M | -28.35M | -23.09M | -24.71M | -16.41M |
| Net income | -22.25M | -25.94M | -20.17M | -21.56M | -12.93M |
| Basic EPS | -0.52 | -0.72 | -0.56 | -0.6 | -0.36 |
| Diluted EPS | -0.52 | -0.72 | -0.56 | -0.6 | -0.36 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 397.65M | 294.89M | 305.09M | 322.15M | 343.84M |
| Total liabilities | 18.53M | 22.84M | 27.63M | 27.37M | 30.67M |
| Total equity | 379.12M | 272.05M | 277.46M | 294.78M | 313.17M |
| Cash & equivalents | 241.78M | 188.89M | 215.57M | 220.33M | 257.49M |
| Current assets | 391.86M | 286.79M | 290.83M | 301.7M | 324.81M |
| Current liabilities | 15.83M | 20.14M | 24.49M | 22.84M | 23.74M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -24.05M | -28.25M | -16.04M | -19.97M | -17.36M |
| Investing cash flow | -46.75M | -14.43M | 12.84M | -15.64M | -77.99M |
| Financing cash flow | 123.72M | 16.01M | -1.54M | -1.5M | -1.5M |
| Change in cash | 52.89M | -26.69M | -4.76M | -37.16M | -96.86M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SCHEDULE 13G/A — BioAge Labs, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — BioAge Labs, Inc. | View Filing | |
| edgar index | 10-Q — BioAge Labs, Inc. | View Filing | |
| edgar index | 8-K — BioAge Labs, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — BioAge Labs, Inc. | View Filing | |
| edgar index | 4 — BioAge Labs, Inc. | View Filing | |
| form 4 | Form 4 — GOLDSTEIN DOV A MD | View Filing | |
| form 4 | Form 4 — GOLDSTEIN DOV A MD | View Filing | |
| edgar index | DEF 14A — BioAge Labs, Inc. | View Filing | |
| edgar index | DEFA14A — BioAge Labs, Inc. | View Filing | |
| edgar index | ARS — BioAge Labs, Inc. | View Filing | |
| edgar index | 4 — BioAge Labs, Inc. | View Filing | |
| edgar index | 144 — BioAge Labs, Inc. | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| edgar index | 8-K — BioAge Labs, Inc. | View Filing | |
| edgar index | 10-K — BioAge Labs, Inc. | View Filing | |
| edgar index | S-8 — BioAge Labs, Inc. | View Filing | |
| edgar index | S-3ASR — BioAge Labs, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 4 — BioAge Labs, Inc. | View Filing | |
| edgar index | 4 — BioAge Labs, Inc. | View Filing | |
| edgar index | 144 — BioAge Labs, Inc. | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| form 4 | Form 4 — GOLDSTEIN DOV A MD | View Filing | |
| form 4 | Form 4 — GOLDSTEIN DOV A MD | View Filing | |
| edgar index | 4 — BioAge Labs, Inc. | View Filing | |
| edgar index | 4 — BioAge Labs, Inc. | View Filing | |
| edgar index | 4 — BioAge Labs, Inc. | View Filing | |
| edgar index | 4 — BioAge Labs, Inc. | View Filing | |
| edgar index | 4 — BioAge Labs, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — BioAge Labs, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — BioAge Labs, Inc. | View Filing | |
| form 4 | Form 4 — GOLDSTEIN DOV A MD | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| form 4 | Form 4 — Barton Shane | View Filing | |
| form 4 | Form 4 — Fortney Kristen | View Filing | |
| form 4 | Form 4 — Morgen Eric | View Filing | |
| form 4 | Form 4 — Morgen Eric | View Filing | |
| edgar index | SCHEDULE 13G/A — BioAge Labs, Inc. | View Filing | |
| edgar index | 4 — BioAge Labs, Inc. | View Filing | |
| edgar index | 4 — BioAge Labs, Inc. | View Filing | |
| edgar index | 144 — BioAge Labs, Inc. | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| form 4 | Form 4 — RUBIN PAUL D | View Filing | |
| form 4 | Form 4 — GOLDSTEIN DOV A MD | View Filing | |
| form 4 | Form 4 — GOLDSTEIN DOV A MD | View Filing | |
| edgar index | 424B5 — BioAge Labs, Inc. | View Filing | |
| edgar index | 8-K — BioAge Labs, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — BioAge Labs, Inc. | View Filing | |
| edgar index | 8-K — BioAge Labs, Inc. | View Filing | |
| edgar index | 424B5 — BioAge Labs, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — GOLDSTEIN DOV A MD | View Filing | |
| form 4 | Form 4 — GOLDSTEIN DOV A MD | View Filing | |
| edgar index | 4 — BioAge Labs, Inc. | View Filing | |
| edgar index | 4 — BioAge Labs, Inc. | View Filing | |
| edgar index | 144 — BioAge Labs, Inc. | View Filing | |
| edgar index | 144 — BioAge Labs, Inc. | View Filing | |
| form 4 | Form 4 — GOLDSTEIN DOV A MD | View Filing |